Drug Profile
Abciximab biosimilar - Primrose Bio
Alternative Names: Monoclonal antibody 7E3 - Primrose BioLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 01 Jan 2015 No development reported for Vascular disorders in USA (IV)